Step-up ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	3

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03917303 (ClinicalTrials.gov)	December 23, 2019	5/4/2019	Control Crohn Safe Trial	Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study.	Crohn Disease;Inflammatory Bowel Diseases	Drug: Adalimumab;Drug: standard step-up care	Maastricht University Medical Center	Maastricht University;ZonMw: The Netherlands Organisation for Health Research and Development	Recruiting	18 Years	70 Years	All	158	Phase 4	Netherlands
2	EUCTR2017-004588-11-NL (EUCTR)	10/09/2019	10/09/2019	Control Crohn Safe Trial: Long term outcome and tolerability of six months adalimumab as initial treatment for newly diagnosed Crohn's disease versus standard step-up treatment.	Control Crohn Safe Trial: Long term efficacy and safety of periodic treatment with adalimumab versus standard step-care for newly diagnosed Crohn's disease. - CoCroS trial	The chronic inflammatory bowel disease Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira	University Maastricht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	158	Phase 4	Netherlands
3	NCT01752790 (ClinicalTrials.gov)	December 2012	12/12/2012	Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease	Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial	Pediatric Crohn's Disease	Drug: Top-down;Drug: Step-up	University of Roma La Sapienza	NULL	Withdrawn	6 Years	18 Years	Both	0	Phase 4	Italy